High Dose Aflibercept in Diabetic Macular Edema in Patients With Previous Vitrectomy
NCT06662994
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
Patients with diabetic macular edema (DME) sometimes must undergo vitrectomy surgery (PPV) for diabetic and non-diabetic related issues. Patients may have improved DME with anti-VEGF therapy and ranibizumab has been found to reduce central macular thickness (CMT) with anti-VEGF therapy following vitrectomy. Those patients still require intravitreal injections but the pharmacokinetics of a vitrectomized eye are different than those eyes that have not undergone vitrectomy.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Diabetic Macular Edema (DME)
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 4
- Ages
- 21 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Retina Consultants of Orange County
- Last updated on ClinicalTrials.gov
- July 10, 2025
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- Retina Consultants of Orange County · Fullerton, CA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.